Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you ...

Pfizer stock offers 30% upside with strong non-COVID franchises, margin expansion, and pipeline potential. Click here to read ...

Pfizer (PFE) is reiterated as a Buy, supported by the world's largest drug pipeline and trading below intrinsic value, ...

Pfizer's coronavirus vaccine could face some headwinds in the near future. The company will enter a period of patent cliffs ...

Pfizer has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock ...

According to Benzinga Pro, Pfizer Inc's peer group average for short interest as a percentage of float is 3.63%, which means ...

Pfizer (PFE) ended the recent trading session at $25.78, demonstrating a +1.78% change from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 0.68 ...

Founded 170 years ago and currently headquartered in New York, Pfizer Inc. (PFE) is a global biopharmaceutical powerhouse ...

Pfizer delivered strong 3Q25 results, beating EPS and revenue estimates, and raised full-year EPS guidance while maintaining robust cost-saving targets. PFE's $10B acquisition of Metsera secures a ...

Morgan Stanley ($MS) has issued a less optimistic outlook on the performance of the shares of American pharmaceutical giant Pfizer ($PFE) for ...